



Center for Industrial Base Management and Supply Chain

ASPR's Center for Industrial Base Management and Supply Chain (IBMSC) aims to build a diverse, agile public health supply chain and sustain long-term U.S. manufacturing capabilities by investing in medical product Industrial Base Expansion (IBx) capacities that enable the United States to respond to health emergencies.

IBMSC has five distinct program offices that invest in domestic manufacturing for medical countermeasures in the following areas.

Defense Production Act: IBMSC leverages Defense Production Act (DPA) authorities to build a robust and resilient public health supply chain capable of responding to emergency public health threats. These authorities can be used across the federal government to ensure that the domestic industrial base can provide essential materials and goods necessary and appropriate for the national defense.

Enabling Innovations and Technology: The Enabling Innovations and Technology Office advances the development, deployment, and on-shoring of manufacturing capacities for Key Starting Materials, Drug Substances, and Drug Products that enables population-scale fill/finish and agile and distributed cGMP compliant production of pharmaceuticals and supportive care fluids.

Supply Chain Optimization: By leveraging data analytics, economic forecasting, industry engagement, and forward-looking assessments, Supply Chain Optimization helps ensure the availability of critical medical products before, during, and after national emergencies.

Testing and Diagnostics: The Office of Testing and Diagnostics prepares the nation's diagnostics apparatus for future threats and helps ensure the security of the nation's medical supply chain.

Critical Medical Equipment: The goal of the Office of Critical Medical Equipment is to ensure the U.S. government, and the entire healthcare sector, can acquire domestically produced sources of critical medical equipment to protect first responders and the American people.

IBMSC Investments to Date

Operational Saline Shield

13.9M

United delivered through
98 airbridge missions

Defense Production Act (DPA) priority rating authority used to expedite delivery of critical products necessary for remediation and restart of the facility

Enabling Innovation and Technology

22

Total
investments

17

Active
investments

\$1.865B

Total value of investments to date

Established capacities across 5 states focused on drug production (100s of millions of doses), population-scale fill/finish and distributed sterile saline manufacturing

Testing and Diagnostics

93

Total
investments

25

Active
investments

\$14B

Total value of
investments

\$700M

SNS operation for
warehousing and
distribution of test kits

21

States with
established
capacities

5

States with test kit
warehouses

\$12.8B

Testing investments

\$625M

Value of upcoming
OTC test
sustainment awards

DPA - Issued priority ratings on 6 investments to ensure availability of manufacturing supplies

Critical Medical Equipment

20

Total
investments

8

Active
investments

\$1.3B

Total value of investments to date

\$370M

Value of 7 more actions for 1QFY23

16

States with established capacities

Meeting previously unattainable goals for nitrile gloves, mask and N95 respirator manufacturing.

Defense Production Act Title III

6

Total investments
Through BioMap
Consortium

Presidential Determination 2023:

...pursuant to section 303(a)(5) of the DPA, Essential medicines, MCMs, and critical inputs... are essential to the national defense

\$300M

Total value of API/KSMs
Investments

+

\$37M

Total value of sterilization
investments

DPA - Issued priority ratings on investments to ensure availability of supplies